Fannin Innovation Studio

Procyrion develops technology solutions and offers a catheter-based circulatory support technologies. One in five adults over the age of 40 will develop heart failure in his or her lifetime. For the sickest patients, only 1% receive treatment annually due to scarcity, cost, and high risk of current solutions. Procyrion, has developed a solution: Aortix is a circulatory support pump implanted without surgery. Thinner than a #2 pencil, a cardiologist can implant Aortix through a catheter in the leg, deploying it between the heart and the kidneys to unload the failing heart and perfuse vital organs. This first-in-class device allows the heart to rest and heal while correcting the fluid imbalance. The company was founded in 2005 and is based in Houston, Texas.

Allterum Therapeutics is a biopharmaceutical company focused on developing targeted treatments for relapsed acute lymphoblastic leukemia and other cancers characterized by IL-7 receptor expression. The company is advancing a monoclonal antibody, originally developed at the National Cancer Institutes, which is designed to specifically target and eliminate cancer cells while minimizing the side effects commonly associated with traditional chemotherapy. In addition to acute lymphoblastic leukemia, Allterum is also exploring the potential of this antibody for use in treating relapsed or refractory solid tumors with IL-7 receptor over-expression, aiming to provide effective therapeutic options for pediatric patients with complex cancer types.

Procyrion develops technology solutions and offers a catheter-based circulatory support technologies. One in five adults over the age of 40 will develop heart failure in his or her lifetime. For the sickest patients, only 1% receive treatment annually due to scarcity, cost, and high risk of current solutions. Procyrion, has developed a solution: Aortix is a circulatory support pump implanted without surgery. Thinner than a #2 pencil, a cardiologist can implant Aortix through a catheter in the leg, deploying it between the heart and the kidneys to unload the failing heart and perfuse vital organs. This first-in-class device allows the heart to rest and heal while correcting the fluid imbalance. The company was founded in 2005 and is based in Houston, Texas.

Pulmotect, Inc. is a biopharmaceutical company focused on developing inhaled therapeutics aimed at preventing and treating respiratory infections, particularly in cancer patients with compromised immune systems. Founded in 2007 and headquartered in Houston, Texas, the company offers PUL-042, a clinical stage inhaled therapeutic that rapidly stimulates the innate immune system, providing immediate and effective protection against a wide range of pathogens, including bacterial pneumonia, influenza, and fungal pneumonia, as well as threats from Class A bioterror agents such as anthrax and plague. By enhancing the body’s natural defenses, Pulmotect's products aim to significantly reduce morbidity and mortality associated with severe respiratory diseases.

Pulmotect, Inc. is a biopharmaceutical company focused on developing inhaled therapeutics aimed at preventing and treating respiratory infections, particularly in cancer patients with compromised immune systems. Founded in 2007 and headquartered in Houston, Texas, the company offers PUL-042, a clinical stage inhaled therapeutic that rapidly stimulates the innate immune system, providing immediate and effective protection against a wide range of pathogens, including bacterial pneumonia, influenza, and fungal pneumonia, as well as threats from Class A bioterror agents such as anthrax and plague. By enhancing the body’s natural defenses, Pulmotect's products aim to significantly reduce morbidity and mortality associated with severe respiratory diseases.

Procyrion develops technology solutions and offers a catheter-based circulatory support technologies. One in five adults over the age of 40 will develop heart failure in his or her lifetime. For the sickest patients, only 1% receive treatment annually due to scarcity, cost, and high risk of current solutions. Procyrion, has developed a solution: Aortix is a circulatory support pump implanted without surgery. Thinner than a #2 pencil, a cardiologist can implant Aortix through a catheter in the leg, deploying it between the heart and the kidneys to unload the failing heart and perfuse vital organs. This first-in-class device allows the heart to rest and heal while correcting the fluid imbalance. The company was founded in 2005 and is based in Houston, Texas.